share_log

康希諾生物:有關董事會、董事會委員會及監事會的選舉

CANSINOBIO: ELECTIONS RELATING TO BOARD OF DIRECTORS, BOARD COMMITTEES AND BOARD OF SUPERVISORS

香港交易所 ·  Feb 23 07:31
Summary by Moomoo AI
康希諾生物於2024年2月23日完成了第三屆董事會及監事會的選舉。Xuefeng YU博士被選為董事會主席,並在同日的董事會第一次會議上,選出了三個董事會委員會的成員。此外,周媛女士在職工代表大會上被選為第三屆監事會職工代表監事,而肖治先生則當選為監事會主席。選舉結果使得公司現已符合香港上市規則對董事會及監事會組成的相關規定。所有選舉均自2024年2月23日起生效。
康希諾生物於2024年2月23日完成了第三屆董事會及監事會的選舉。Xuefeng YU博士被選為董事會主席,並在同日的董事會第一次會議上,選出了三個董事會委員會的成員。此外,周媛女士在職工代表大會上被選為第三屆監事會職工代表監事,而肖治先生則當選為監事會主席。選舉結果使得公司現已符合香港上市規則對董事會及監事會組成的相關規定。所有選舉均自2024年2月23日起生效。
CONXINO BIO COMPLETED ITS ELECTION TO ITS THIRD BOARD AND SUPERVISORY BOARD ON FEBRUARY 23, 2024. Dr. Xuefeng YU was elected Chairman of the Board of Directors, and at the first meeting of the Board of Directors on the same day, three members of the Board Committee were elected. In addition, Ms. Zhou Yuan was elected as the Supervisor for the third term of the Board of Supervisors at the Working Workers' Representative Conference, and Mr. Shaoxi was elected Chairman of the Board. The election results enable the company to now comply with the relevant provisions of the Hong Kong Listing Rules on the composition of the Board of Directors and Supervisory Boards. All elections are effective from 23 February 2024.
CONXINO BIO COMPLETED ITS ELECTION TO ITS THIRD BOARD AND SUPERVISORY BOARD ON FEBRUARY 23, 2024. Dr. Xuefeng YU was elected Chairman of the Board of Directors, and at the first meeting of the Board of Directors on the same day, three members of the Board Committee were elected. In addition, Ms. Zhou Yuan was elected as the Supervisor for the third term of the Board of Supervisors at the Working Workers' Representative Conference, and Mr. Shaoxi was elected Chairman of the Board. The election results enable the company to now comply with the relevant provisions of the Hong Kong Listing Rules on the composition of the Board of Directors and Supervisory Boards. All elections are effective from 23 February 2024.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more